We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
Read MoreHide Full Article
Key Takeaways
Bruker posted Q2 EPS of $0.32, missing estimates and falling 38.5% year over year.
BRKR's Q2 revenues dipped 0.4% to $797.4M, with U.S. sales down 8.5% but Asia Pacific up 6.8%.
Bruker cut its full-year guidance on weak demand, tariff impact and U.S. academic market softness.
Bruker Corporation (BRKR - Free Report) delivered adjusted earnings per share (EPS) of 32 cents for the second quarter of 2025, down 38.5% year over year. The figure fell short of the Zacks Consensus Estimate by 3.03%.
The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others.
GAAP EPS was 5 cents, in line with the year-ago period’s figure.
BRKR’s Q2 Revenues
Bruker's second-quarter revenues were $797.4 million, down 0.4% year over year. However, the figure topped the Zacks Consensus Estimate by 0.11%.
Excluding the positive impacts of 3.7% from acquisitions and a 2.9% favorable impact of foreign currency rates, the company’s organic revenues decreased 7%.
Following the Aug. 4 announcement, shares of BRKR fell 7.6% to close at $32.07 on the Aug. 5 session.
BRKR’s Q2 Revenues by Geography
On a geographic basis, U.S. revenues fell 8.5% year over year to $222.9 million.
Europe revenues decreased 1.2% year over year to $272.5 million, while Asia Pacific revenues rose 6.8% to $242.1 million.
Bruker Corporation Price, Consensus and EPS Surprise
The Other category’s revenues increased 9.7% year over year to $59.9 million.
BRKR’s Q2 Segmental Analysis
Bruker reports results under two segments — BSI (comprising BioSpin, CALID and Nano) and Bruker Energy & Supercon Technologies (“BEST”).
Revenues in the BSI segment fell 0.3% to $733.2 million in the second quarter of 2025.
Within the segment, BioSpin Group’s revenues dropped 10.2% from the year-ago quarter’s levels to $195.3 million. The decline was led by weaker demand in the biopharma and industrial markets for life science instruments.
CALID’s revenues rose 7.6% year over year to $285.8 million, mainly due to increased contributions from prior-year acquisitions.
Revenues from the NANO group dipped slightly by 0.2% to $252.1 million.
The BEST segment’s revenues were $66.3 million, down 4.1% year over year. The decrease was due to softness in the clinical MRI market, as well as a strong prior-year comparison for the Research Instruments business.
Bruker’s Q2 Margin Performance
Bruker’s gross profit fell 6.9% to $357.9 million. The gross margin contracted 315 basis points (bps) to 44.9% on a 5.6% rise in the cost of revenues.
SG&A expenses rose 4.5% to $231.4 million. R&D expenses went up 8.7% year over year to $100.2 million. Adjusted operating expenses of $331.6 million increased 5.8% year over year.
The adjusted operating profit was $26.3 million, down 63% from the prior-year quarter’s levels. Meanwhile, the adjusted operating margin contracted 558 basis points (bps) to 3.2%.
BRKR’s Financial Position
Bruker exited the second quarter of 2025 with cash and cash equivalents of $92 million compared with $184.2 million at the end of the first quarter.
The total long-term debt (including the current portion) at the end of the second quarter of 2025 was $2.44 billion compared with $2.11 billion at the first-quarter end.
Cumulative net cash used in operating activities was $127.5 million compared to a cash inflow of $1.1 million during last year’s comparable period.
BRKR’s 2025 Guidance
The company has lowered its financial guidance for full-year 2025, as it awaits greater clarity on U.S. academic funding trends, China stimulus, finalized tariffs, and the timing of a recovery in biopharma drug discovery and industrial research instruments demand.
Bruker now expects revenues in the range of $3.43-$3.50 billion (earlier $3.48 and $3.55 billion), suggesting approximately 2% to 4% year-over-year reported revenue growth. The Zacks Consensus Estimate for revenues is pegged at $3.46 billion.
Adjusted EPS for the year is expected in the range of $1.95-$2.05 (previously $2.40-$2.48) compared with $2.41 in 2024. The consensus estimate for EPS is pegged at $2.12.
Our Take on Bruker
Bruker delivered both earnings and revenues missing estimates in the second quarter of 2025. Both metrics were also down on a year-over-year basis as the company faced challenging demand conditions in the U.S. academic market, as well as in biopharma and industrial markets. Tariffs and currency headwinds outweighed Bruker’s mitigating price, supply chain and cost actions in the second quarter. The contraction of both margins and dismal 2025 guidance are also discouraging.
Meanwhile, Bruker has announced a significantly expanded cost savings initiative that is expected to reduce its annual costs by $100 million-$120 million for fiscal year 2026. These major cost reductions affect all parts of its business, from supply chain and manufacturing to its commercial operations and investments.
BRKR’s Zacks Rank & Key Picks
BRKR currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
Key Takeaways
Bruker Corporation (BRKR - Free Report) delivered adjusted earnings per share (EPS) of 32 cents for the second quarter of 2025, down 38.5% year over year. The figure fell short of the Zacks Consensus Estimate by 3.03%.
The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others.
GAAP EPS was 5 cents, in line with the year-ago period’s figure.
BRKR’s Q2 Revenues
Bruker's second-quarter revenues were $797.4 million, down 0.4% year over year. However, the figure topped the Zacks Consensus Estimate by 0.11%.
Excluding the positive impacts of 3.7% from acquisitions and a 2.9% favorable impact of foreign currency rates, the company’s organic revenues decreased 7%.
Following the Aug. 4 announcement, shares of BRKR fell 7.6% to close at $32.07 on the Aug. 5 session.
BRKR’s Q2 Revenues by Geography
On a geographic basis, U.S. revenues fell 8.5% year over year to $222.9 million.
Europe revenues decreased 1.2% year over year to $272.5 million, while Asia Pacific revenues rose 6.8% to $242.1 million.
Bruker Corporation Price, Consensus and EPS Surprise
Bruker Corporation price-consensus-eps-surprise-chart | Bruker Corporation Quote
The Other category’s revenues increased 9.7% year over year to $59.9 million.
BRKR’s Q2 Segmental Analysis
Bruker reports results under two segments — BSI (comprising BioSpin, CALID and Nano) and Bruker Energy & Supercon Technologies (“BEST”).
Revenues in the BSI segment fell 0.3% to $733.2 million in the second quarter of 2025.
Within the segment, BioSpin Group’s revenues dropped 10.2% from the year-ago quarter’s levels to $195.3 million. The decline was led by weaker demand in the biopharma and industrial markets for life science instruments.
CALID’s revenues rose 7.6% year over year to $285.8 million, mainly due to increased contributions from prior-year acquisitions.
Revenues from the NANO group dipped slightly by 0.2% to $252.1 million.
The BEST segment’s revenues were $66.3 million, down 4.1% year over year. The decrease was due to softness in the clinical MRI market, as well as a strong prior-year comparison for the Research Instruments business.
Bruker’s Q2 Margin Performance
Bruker’s gross profit fell 6.9% to $357.9 million. The gross margin contracted 315 basis points (bps) to 44.9% on a 5.6% rise in the cost of revenues.
SG&A expenses rose 4.5% to $231.4 million. R&D expenses went up 8.7% year over year to $100.2 million. Adjusted operating expenses of $331.6 million increased 5.8% year over year.
The adjusted operating profit was $26.3 million, down 63% from the prior-year quarter’s levels. Meanwhile, the adjusted operating margin contracted 558 basis points (bps) to 3.2%.
BRKR’s Financial Position
Bruker exited the second quarter of 2025 with cash and cash equivalents of $92 million compared with $184.2 million at the end of the first quarter.
The total long-term debt (including the current portion) at the end of the second quarter of 2025 was $2.44 billion compared with $2.11 billion at the first-quarter end.
Cumulative net cash used in operating activities was $127.5 million compared to a cash inflow of $1.1 million during last year’s comparable period.
BRKR’s 2025 Guidance
The company has lowered its financial guidance for full-year 2025, as it awaits greater clarity on U.S. academic funding trends, China stimulus, finalized tariffs, and the timing of a recovery in biopharma drug discovery and industrial research instruments demand.
Bruker now expects revenues in the range of $3.43-$3.50 billion (earlier $3.48 and $3.55 billion), suggesting approximately 2% to 4% year-over-year reported revenue growth. The Zacks Consensus Estimate for revenues is pegged at $3.46 billion.
Adjusted EPS for the year is expected in the range of $1.95-$2.05 (previously $2.40-$2.48) compared with $2.41 in 2024. The consensus estimate for EPS is pegged at $2.12.
Our Take on Bruker
Bruker delivered both earnings and revenues missing estimates in the second quarter of 2025. Both metrics were also down on a year-over-year basis as the company faced challenging demand conditions in the U.S. academic market, as well as in biopharma and industrial markets. Tariffs and currency headwinds outweighed Bruker’s mitigating price, supply chain and cost actions in the second quarter. The contraction of both margins and dismal 2025 guidance are also discouraging.
Meanwhile, Bruker has announced a significantly expanded cost savings initiative that is expected to reduce its annual costs by $100 million-$120 million for fiscal year 2026. These major cost reductions affect all parts of its business, from supply chain and manufacturing to its commercial operations and investments.
BRKR’s Zacks Rank & Key Picks
BRKR currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.